v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Costs and expenses:        
Research and development $ 13,393,464 $ 5,270,967 $ 24,232,614 $ 15,784,546
Selling, general and administrative 7,657,531 5,919,731 15,033,654 11,169,022
Change in fair value 0 (358,420) (373,354) (1,523,284)
Total costs and expenses 21,050,995 10,832,278 38,892,914 25,430,284
Loss from operations (21,050,995) (10,832,278) (38,892,914) (25,430,284)
Other Income 1,459,764 916,755 2,920,843 1,836,026
Net loss (19,591,231) (9,915,523) (35,972,071) (23,594,258)
Unrealized gain (loss) on marketable securities (46,461) (1,977) (94,556) 34,304
Comprehensive loss $ (19,637,692) $ (9,917,500) $ (36,066,627) $ (23,559,954)
Net loss per share - basic $ (0.11) $ (0.11) $ (0.21) $ (0.26)
Net loss per share - diluted $ (0.11) $ (0.11) $ (0.21) $ (0.26)
Weighted-average number of shares_ basic 174,571,543 90,009,625 173,445,493 89,774,703
Weighted-average number of shares_ diluted 174,571,543 90,009,625 173,445,493 89,774,703